课题基金 / 基金详情

项目摘要

项目成果

TATIANA M. FOROUD的其他基金

相似基金

相关文献

中文摘要
翻译
摘要-生物标本/病理学核心 这个孢子的首要目标是了解过度激活的p21 ras的生物学基础 通路信号在儿童恶性神经纤维瘤病1型发病机制中的作用, 治疗到诊所。每个项目都使用不同的疾病模型探索这一主题。然而,所有项目 交织人,小鼠和体外研究,以确定修改Ras的影响因素。确保 这些研究的成功,补充尖端技术将用于解决关键问题 与疾病易感性、疾病复发的可能性和其他恶性肿瘤的风险相关。 生物标本和病理学核心将接收来自所有四个项目的人类和小鼠样本, 孢子。核心还将提供所有样本的病理学审查,并将这些数据提供给所有人 SPORE研究人员和更广泛的研究社区。该核心的具体目标是: 目标1:维护和更新DHART SPORE网站,作为一个有效的内部和外部 沟通工具。 目标2:采用统一的生物样本接收、跟踪和分发程序, 关于DHART SPORE项目 目标3:应用统一的病理学方案对人类和动物样本进行表征 作为DHART SPORE项目的一部分收集。
英文摘要
ABSTRACT – BIOSPECIMEN/PATHOLOGY CORE The overarching goal of this SPORE is to understand the biological underpinnings of hyperactivated p21ras pathway signals in the pathogenesis of childhood malignancies of neurofibromatosis type 1 and to bring new therapies to the clinic. Each project explores this theme using a different disease model. However, all projects interweave human, mouse and in vitro studies to identify factors that modify the effects of Ras. To ensure the success of these studies, complementary cutting-edge technologies will be used to address key questions related to disease susceptibility, likelihood of disease relapse, and risk for other malignancies. The Biospecimen and Pathology Core will receive human and mouse samples from all four projects in the SPORE. The core will also provide pathological review of all samples and will make these data available to all SPORE investigators and the broader research community. The specific aims of this core are: Aim 1: Maintain and update the DHART SPORE website as an effective internal and external communication tool. Aim 2: Utilize uniform biospecimen receipt, tracking and distribution procedures for samples collected as part of DHART SPORE projects. Aim 3: Apply uniform pathology protocols for the characterization of human and animal samples collected as part of DHART SPORE projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biospecimen Exchange for Neurological Disorders (BioSEND)
Genetic, Biomarker and Biospecimen Core
Genetic, Biomarker and Biospecimen Core
Biospecimen Exchange for Neurological Disorders (BioSEND)
海外基金